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Abstract: Molecular classification has improved the knowledge of medulloblastoma (MB), the most
common malignant brain tumour in children, however current treatments cause severe side effects
in patients. Cancer stem cells (CSCs) have been described in MB and represent a sub population
characterised by self-renewal and the ability to generate tumour cells, thus representing the reservoir
of the tumour. To investigate molecular pathways that characterise this sub population, we isolated
CSCs from Sonic Hedgehog Medulloblastoma (SHH MB) arisen in Patched 1 (Ptch1) heterozygous
mice, and performed miRNA- and mRNA-sequencing. Comparison of the miRNA-sequencing of
SHH MB CSCs with that obtained from cerebellar Neural Stem Cells (NSCs), allowed us to obtain
a SHH MB CSC miRNA differential signature. Pathway enrichment analysis in SHH MB CSCs
mirnome and transcriptome was performed and revealed a series of enriched pathways. We focused
on the putative targets of the SHH MB CSC miRNAs that were involved in the enriched pathways
of interest, namely pathways in cancer, PI3k-Akt pathway and protein processing in endoplasmic
reticulum pathway. In silico analysis was performed in SHH MB patients and identified several
genes, whose expression was associated with worse overall survival of SHH MB patients. This study
provides novel candidates whose functional role should be further investigated in SHH MB.
Keywords: microRNAs; cancer stem cells; medulloblastoma; Sonic Hedgehog pathway; RNA-sequencing
1. Introduction
Medulloblastoma (MB) is the most common malignant brain tumour in childhood. Multimodal
aggressive treatments include surgical resection and chemo- and radio-therapy, and are able to
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cure about 70% of patients. Unfortunately, due to these cytotoxic and aggressive therapies,
survivors often face severe side effects. Moreover, one third of patients still die of disease due
to relapse and metastasis. Recent years have witnessed an intense molecular characterisation of
MBs, according to the genetic structure, gene expression pattern, and methylation profile [1–5]
with the final aim to correlate molecular features to risk categories, a better management of MB
patients, and the identification of molecular targets and molecular pathways to be exploited as
new therapeutic strategies. Despite being initially characterised according to histological features,
the 2016 WHO consensus conference envisaged five subgroups: Wingless-type MMTV integration
site family (WNT) activated, Sonic Hedgehog (SHH) activated P53 wild-type, SHH activated P53
mutant, non-WNT/non-SHH Group 3, non-WNT/non-SHH Group 4 [6]. Research groups continue
implementing and integrating molecular and clinical features, and recent reports described up to
12 molecular subtypes that more deeply characterise the 4 subgroups that were originally described by
Northcott [4]: WNT has 2 subtypes (α and β), SHH has 4 subtypes (α, β, γ and δ), group 3 and 4 have
3 subtypes each (α, β and γ) [2].
Among MB molecular subgroups, SHH subgroups (P53 wild-type and mutant) according to WHO,
α, β, γ, and δ according to Cavalli et al. [2] account for roughly 24–30% of cases. Attempts were carried
out recently to identify possible therapeutic targets, with particular efforts to find drugs targeting
Smoothened (SMO) [7,8], the upstream regulator of the pathway. However, despite good results
in other SHH driven cancers, such as basal cell carcinoma [9–11], in SHH MB the initial response
was followed by resistance and progression of disease [12,13]. As a result, the crosstalk of SHH
pathway with other pathways [14] should be taken into account in the design and development
of novel drugs since tumour escape has been reported. Recently, two novel SMO inhibitors,
based on Vismodegib (GDC-0449), decreased Ptch+/−/p53−/− MB allograft tumour growth [15],
however further investigations are required before a possible clinical trial.
Cancer stem cells (CSCs) may arise from the malignant transformation of neural stem cells (NSCs)
of more committed progenitors [16] and have been described from MB [17]. There are several SHH
based MB mouse models [18]. Goodrich et al. [19] established a model based on the mutation of
Ptch, the transmembrane receptor of SHH that also functions as a tumor suppressor and reported
that a subset of Ptch heterozygotes spontaneously develops MB. We previously isolated CSCs from
human and murine Ptch heterozygous SHH MB [20–23] and we demonstrated that they share common
features with NSCs derived from postnatal cerebellum [20]. Indeed, SHH MB CSCs and NSCs are
both sustained by the Hedgehog (HH) signaling pathway using the glioma-associated oncogene
homolog to up-regulate the stemness factor Nanog [20]. Moreover, we showed that NFκB (Nuclear
factor Kappa B DNA binding subunit), a transcription regulator, has a role in the sustenance of human
SHH MB CSCs [21]. Interestingly, we identified several upstream regulators of NFκB [21] such as NPM
(Nucleophosmin), PCNA (Proliferating Nuclear Antigen), P65 (Nuclear Factor Kappa B Transcription
Factor P65), and HSPA1A (Heat Shock Protein Family A [Hsp70] Member 1A) potentially involved in
the induction of aberrant cell growth and proliferation in human SHH MB CSCs through the combined
analysis of proteomics and microRNA (miRNA) expression profiles [22]. The importance of HH–GLI
signaling in tumour maintenance and stemness properties [24] has been also described in other CSC
contexts, such as colon and lung cancer, in various ways for instance through a non-canonical signalling,
involving NRP2 (Neuropilin 2) and MAP/ERK (Mitogen Activated Protein Kinase/Extracellular
Signal-Regulated Kinase) signalling [25].
Since CSCs are considered to be the ultimate reservoir of cancer and responsible for relapse and
metastasis, it is thus of great interest to investigate molecular mechanisms represented at high levels in
these cells.
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2. Results and Discussion
2.1. miRNA-Sequencing Determines miRNA Signatures in SHH MB CSCs
SHH MB CSCs were subjected to small RNA sequencing and miRNA expression levels were
compared to our recently published NSC mirnome [26]. Hierarchical clustering of the differentially
expressed miRNAs yielded two distinct clusters, clearly distinguishing SHH MB CSCs and NSCs
(Figure 1). In detail, SHH MB CSCs were characterised by 35 up-regulated and 133 down-regulated
miRNAs (Tables 1 and 2 report the top 20 miRNAs, respectively; the entire datasets are in Tables S1 and
S2). Results of the miRNA-sequencing were validated at the transcriptional level by quantitative PCR.
Higher expression of miR-20a-5p and miR-193a-5p and lower expression of miR-222-5p, miR-34a-5p,
miR-345-5p, miR-210-5p, and miR-200a-3p were confirmed in SHH MB CSCs compared to NSCs (marked
in bold in Tables S1 and S2, Figure 2). The SHH MB CSC miRNA signature included several miRNAs
that have been described in primary MBs [27–30]. Specifically, among miRNAs characterising SHH MB
CSCs, we identified let-7a, miR-100, miR-132, miR-135a, miR-135b, miR-150, and miR-203, which we had
previously described as deregulated miRNAs in primary human SHH MBs (originally named Glihigh) in
respect to non-SHH MBs (Glilow) [27]. Moreover, miR-135b and miR-203 were similarly down-regulated
as in Glihigh in respect to Glilow MBs, possibly representing the MB CSC compartment. Northcott et
al. [30] performed a comparison between MB subgroups and identified a number of SHH MB-related
miRNAs, several of which were deregulated in SHH MB CSCs, such as miR-20a, miR-17, miR-135a,
miR-106a, miR-222, miR-135b, and miR-203. Of particular interest are the up-regulated miRNAs (miR-20a
and miR-17) and the down-regulated miRNAs (miR-135b and miR-203) that were similarly expressed in
both studies. Moreover, in the same study of Northcott et al. the expression of miRNAs in Shh-treated
cerebellar granule neuron precursors (CGNPs) is reported and miR-19b, miR-714, and miR-709 showed a
coherent deregulation with SHH MB CSCs. We previously reported miRNAs expressed in primary MBs
compared to normal adult and fetal human cerebellum [28]. Interestingly, thirteen miRNAs deregulated
in primary MB were also deregulated in SHH MB CSCs (miR-203, miR-361, miR-31, miR-17, miR-20a,
miR-106a, miR-let-7a, miR-132, miR-150, miR-212, miR-330, miR-29a, and miR-135a) and of particular
interest miR-203, miR-361, miR-31, miR-17, and miR-20a were expressed in a similar fashion in both
primary MBs and SHH MB CSCs. Further studies have been performed focusing on miRNA expression
in MB mouse models and as a result the collaboration of miR-17~92 cluster with the HH pathway in MB
and its up-regulation in SHH MB [29,31].
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Table 1. Top 20 up-regulated miRNAs in Sonic Hedgehog Medulloblastoma Cancer Stem Cells (SHH
MB CSCs) vs. Neural Stem Cells (NSCs). The entire dataset is reported in Table S1; adj., adjusted.
miRNA Log2 (Fold-Change) adj. p-Value
mmu-miR-466i-5p 5.49 3.90 × 10−3
mmu-miR-615-3p 4.51 4.43 × 10−2
mmu-miR-871-3p 3.87 2.54 × 10−4
mmu-miR-708-3p 3.30 2.69 × 10−2
mmu-miR-135a-5p 2.90 4.10 × 10−2
mmu-miR-212-3p 2.83 4.19 × 10−2
mmu-miR-193a-5p 2.79 2.25 × 10−2
mmu-miR-330-5p 2.72 3.73 × 10−2
mmu-miR-212-5p 2.62 3.73 × 10−2
mmu-miR-193a-3p 2.50 8.88 × 10−7
mmu-miR-132-3p 2.49 4.43 × 10−2
mmu-miR-466h-3p 2.38 4.92 × 10−2
mmu-miR-150-5p 2.17 2.16 × 10−2
mmu-miR-139-5p 2.14 4.18 × 10−2
mmu-miR-195a-5p 2.11 5.53 × 10−4
mmu-miR-145a-5p 2.05 4.43 × 10−2
mmu-miR-146a-5p 2.03 3.26 × 10−3
mmu-miR-92a-1-5p 1.94 5.98 × 10−3
mmu-miR-23b-3p 1.84 3.43 × 10−2
mmu-miR-365-2-5p 1.84 3.20 × 10−2
Table 2. Top 20 down-regulated miRNAs in SHH MB CSCs vs. NSCs. The entire dataset is reported in
Table S2; adj., adjusted.
miRNA log2 (Fold-Change) adj. p-Value
mmu-miR-8102 −11.57 2.85 × 10−26
mmu-miR-28c −10.88 5.04 × 10−31
mmu-miR-486-3p −9.67 1.56 × 10−20
mmu-miR-34a-5p −8.66 3.04 × 10−44
mmu-miR-3084-5p −8.48 3.90 × 10−20
mmu-miR-3080-3p −7.77 1.87 × 10−9
mmu-miR-6922-5p −7.44 2.27 × 10−12
mmu-miR-5122 −7.16 6.19 × 10−9
mmu-miR-31-5p −7.02 1.68 × 10−10
mmu-miR-219c-5p −6.93 1.00 × 10−17
mmu-miR-6944-5p −6.91 1.11 × 10−8
mmu-miR-106a-5p −6.79 9.35 × 10−9
mmu-let-7k −6.78 9.79 × 10−12
mmu-miR-3074-5p −6.40 2.11 × 10−12
mmu-miR-7036b-5p −6.37 1.98 × 10−8
mmu-miR-7081-3p −6.29 6.37 × 10−14
mmu-miR-6936-3p −6.07 1.11 × 10−8
mmu-miR-7066-5p −6.03 2.92 × 10−6
mmu-miR-378b −6.01 1.37 × 10−10
mmu-miR-5099 −5.99 9.79 × 10−12
Int. J. Mol. Sci. 2018, 19, 2326 5 of 19
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 19 
 
 
Figure 2. Quantitative PCR validation of mirnome in SHH MB CSC versus NSC. miRNA expression 
level of miRNAs (miR-20a-5p, miR-222-5p, miR-34a-5p, miR-345-5p, miR-210-5p, miR-193a-5p, and 
miR-200a-3p) in SHH MB CSCs vs. NSCs. Data are normalised versus endogenous control: U6. 
Results are shown in relative expression and data are means ± SD from three independent 
experiments. p-values * p < 0.05; ** p < 0.01. 
2.2. Enriched Pathway Analysis of SHH MB CSCs Transcriptome and Mirnome 
SHH MB CSCs were next subjected to mRNA-sequencing and transcripts were ranked 
according to their expression (Table S3). mRNA-sequencing results were validated at the 
transcriptional level by quantitative PCR. Higher expression of Ccnd1, Hdac2, Atf4, Bcat1, Ccnd2, Myc 
and Hiflf1a was confirmed in SHH MB CSCs, whereas higher expression of Cdkn1a and Egfr was 
confirmed in NSCs (Figure 3). In order to determine the enriched pathways of SHH MB CSCs, 
pathway enrichment analysis was performed. The statistically significant pathways with the highest 
gene count, and thus most affected, are reported in Figure 4A. Among them, the decrease on oxidative 
phosphorylation has already been described in MB and the combinatorial targeting of MB metabolism 
has been proposed for effective treatments [32]. Of equal interest is the protein processing in 
endoplasmic reticulum pathway since endoplasmic reticulum stress has been reported to promote 
angiogenesis, invasiveness, and MB tumour growth in a murine model [33]. Moreover, the enrichment 
of PI3K-Akt signalling pathway and pathways in cancer were identified. The PI3K-Akt/mTOR 
pathway has been reported to be activated in MB [34–36], involved in metastasis [37] and its targeting 
has been proposed to inhibit MB CSCs [38] and overcome resistance to SMO antagonists [39]. All 
enriched pathways along with their matching genes are listed in Table 3 and Table S4, findings are 
ranked according to observed gene count. 
mm
u-m
iR-2
0a-
5p
mm
u-m
iR-2
22-
5p
mm
u-m
iR-3
4a-
5p
mm
u-m
iR-3
45-
5p
mm
u-m
iR-2
10-
5p
mm
u-m
iR-1
93a
-5p
mm
u-m
iR-2
00a
-3p
0
2
4
6
8
10
500
1000
mi
RN
A r
ela
tiv
e e
xp
res
sio
n SHH MB CSC
NSC
* 
** 
** 
* * * 
** 
Figure 2. Quantitative PCR validation of mirnome in SHH MB SC versus NSC. miRNA expression
l vel of miRNAs (miR-20a-5p, miR-222-5p, miR-34a-5p, miR-345-5p, miR-210-5p, miR-193a-5p,
and miR-200a-3p) in SHH MB CSCs vs. NSCs. Data are normali ed versus endogenous control:
U6. Results are shown in relative expression and data ar means ± SD from three ind pendent
experiments. p-values * p < 0.05; ** p < 0.01.
2.2. Enriched Pathway Analysis of SHH MB CSCs Transcriptome and Mirnome
SHH MB CSCs were next subjected to mRNA-sequencing and transcripts were ranked according
to their expression (Table S3). mRNA-sequencing results were validated at the transcriptional level
by quantitative PCR. Higher expression of Ccnd1, Hdac2, Atf4, Bcat1, Ccnd2, Myc and Hiflf1a was
confirmed in SHH MB CSCs, whereas higher expression of Cdkn1a and Egfr was confirmed in NSCs
(Figure 3). In order to determine the enriched pathways of SHH MB CSCs, pathway enrichment
analysis was performed. The statistically significant pathways with the highest gene count, and thus
most affected, are reported in Figure 4A. Among them, the decrease on oxidative phosphorylation has
already been described in MB and the combinatorial targeting of MB metabolism has been proposed
for effective treatments [32]. Of equal interest is the protein processing in endoplasmic reticulum
pathway since endoplasmic reticulum stress has been reported to promote angiogenesis, invasiveness,
and MB tumour growth in a murine model [33]. Moreover, the enrichment of PI3K-Akt signalling
pathway and pathways in cancer were identified. The PI3K-Akt/mTOR pathway has been reported to
be activated in MB [34–36], involved in metastasis [37] and its targeting has been proposed to inhibit
MB CSCs [38] and overcome resistance to SMO antagonists [39]. All enriched pathways along with
their matching genes are listed in Table 3 and Table S4, findings are ranked according to observed
gene count.
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#Pathway ID Pathway Description Observed Gene Count False Discovery Rate
1100 Metabolic pathways 216 1.90 × 10−27
5016 Huntington’s disease 92 2.54 × 10−51
3010 Ribosome 91 3.04 × 10−69
19 Oxidative phosphorylation 83 6.82 × 10−56
5012 Parkinson’s disease 81 6.49 × 10−50
5010 Alzheimer’s disease 79 9.89 × 10−41
4932 Non-alcoholic fatty liver disease (NAFLD) 65 2.16 × 10−30
4141 Protein processing in endoplasmic reticulum 64 2.92 × 10−26
3040 Spliceosome 63 9.69 × 10−34
5169 Epstein–Barr virus infection 54 2.04 × 10−14
3013 RNA transport 52 1.98 × 10−17
4151 PI3K-Akt signaling pathway 48 7.44 × 10−4
1120 Microbial metabolism in diverse environments 47 5.73 × 10−13
5200 Pathways in cancer 46 5.82 × 10−4
1200 Carbon metabolism 44 2.69 × 10−19
4110 Cell cycle 44 6.66 × 10−17
4120 Ubiquitin medi ted proteolysis 40 4.50 × 10−12
5203 Viral carcinogenesis 40 6.48 × 10−7
4810 Regulation of actin cytoskeleton 40 5.49 × 10−6
5205 Proteoglycans in cancer 40 1.07 × 10−5
Accordingly, pathway enrichment analysis was performed for the SHH MB CSC miRNAs.
In detail, up-regulated and down-regulated miRNAs were used as inputs and 25 pathways were
reported as statistically significant for each input (Tables 4 and 5 report the top 20 pathways. The entire
tables are reported in Tables S5 and S6). Since we were interested in the identification of the
pathways characterising SHH MB CSCs, we focused on the intersection of the enriched pathways
between the SHH MB CSC miRNAs and their transcriptome. Pathways in cancer, PI3K-Akt pathway,
and protein processing in endoplasmic reticulum were the three common pathways identified by the
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intersection between the enriched pathways of the up-regulated miRNAs and those of the SHH MB CSC
transcriptome (Figure 4B). Whereas, only two pathways were in common between the down-regulated
miRNAs in SHH MB CSCs and their transcriptome, as shown in Figure 4B, pathways in cancer and
PI3K-Akt pathway.
Table 4. Top 20 KEGG pathways from enrichment analysis of up-regulated miRNAs in SHH MB CSC.
The entire table is reported in Table S5.
KEGG Pathway p-Value #Genes #miRNAs
Pathways in cancer 4.18 × 10−8 152 31
PI3K-Akt signaling pathway 1.28 × 10−5 130 30
MAPK signaling pathway 5.32 × 10−6 100 31
Focal adhesion 1.59 × 10−6 91 29
Proteoglycans in cancer 4.18 × 10−8 90 28
cAMP signaling pathway 3.92 × 10−6 86 29
Regulation of actin cytoskeleton 5.54 × 10−5 84 30
Hippo signaling pathway 3.92 × 10−6 68 28
Transcriptional misregulation in cancer 4.80 × 10−5 67 27
Axon guidance 2.75 × 10−7 66 26
Protein processing in endoplasmic reticulum 1.26 × 10−4 66 27
FoxO signaling pathway 3.92 × 10−6 63 26
Wnt signaling pathway 3.92 × 10−6 63 27
Signaling pathways regulating pluripotency of stem cells 8.71 × 10−7 62 30
Thyroid hormone signaling pathway 4.53 × 10−7 53 27
Choline metabolism in cancer 8.79 × 10−5 48 28
Prostate cancer 6.35 × 10−6 45 27
ErbB signaling pathway 9.09 × 10−6 45 27
Phosphatidylinositol signaling system 2.15 × 10−6 38 23
Renal cell carcinoma 4.70 × 10−6 35 27
Table 5. Top 20 KEGG pathways from enrichment analysis of down-regulated miRNAs in SHH MB
CSC. The entire table is reported in Table S6.
KEGG Pathway p-Value #Genes #miRNAs
Pathways in cancer 8.24 × 10−7 209 72
PI3K-Akt signaling pathway 3.39 × 10−5 182 70
MAPK signaling pathway 1.41 × 10−6 141 65
Endocytosis 8.24 × 10−7 123 60
Regulation of actin cytoskeleton 5.28 × 10−6 123 62
Focal adhesion 1.45 × 10−5 117 62
Rap1 signaling pathway 2.80 × 10−5 116 65
Proteoglycans in cancer 8.24 × 10−7 114 68
cAMP signaling pathway 4.14 × 10−4 106 69
Hippo signaling pathway 7.77 × 10−8 89 56
Axon guidance 5.69 × 10−8 83 54
FoxO signaling pathway 6.17 × 10−6 82 56
Thyroid hormone signaling pathway 7.84 × 10−8 67 50
TGF-beta signaling pathway 4.67 × 10−4 50 48
ECM-receptor interaction 4.12 × 10−11 48 45
Adherens junction 3.60 × 10−8 48 48
GABAergic synapse 4.93 × 10−8 48 47
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 3.29 × 10−7 46 45
Amphetamine addiction 3.32 × 10−5 41 47
Long-term depression 6.80 × 10−6 39 49
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2.3. Novel Functional Networks in SHH MB CSCs
The binding of miRNA to mRNA is a type of regulation that can control both the translation of
the mRNA and the availability of miRNA for other targets [40], indeed miRNAs post-transcriptional
regulation ca amount to controlling 50% of the protein-coding genes, due to the ability of miRNAs
to target multiple genes [41]. On this basis, we focused on the identification of networks that could
be involved in the perpetuation of SHH MB CSCs using the putative targets of the up-regulated and
down-regulated miRNAs that belong to the common enriched pathways. As reported in Figure 5,
we firstly focused on the networks comprising the putative targets of the up-regulated miRNAs.
Networks in Figure 5A,B show several genes in common, such as Mapk1, Mapk3, Raf1, Fgfr1, Ptk2,
and Itgb1. All of them play a pivotal role in cancer cell growth and maintenance. Specifically, Mapk1 and
Mapk3 activation have been associated with metastatic MB and poor outcomes [42]. Also, resistance to
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SMO inhibition along with metastasis in SHH dependent tumours has been attributed to the activation
of RAS/MAPK pathway [43]. Fgfr1 is a member of the fibroblast growth receptors family and activation
of Fgf signalling has been proposed as a target of MB and other SHH dependent tumours [44].
Similarly, Ptk2, a focal adhesion kinase, has been reported to induce MB cells proliferation and mediate
c-Met migration and invasion [45]. Recently, another study investigated the activation of Itgb1 by
Map4k4 and its association with the infiltration of MB cells [46]. Interestingly, Hsp90b1 was involved in
all three networks (Figure 5A–C). Hsp90b1 is an essential molecular chaperone [47] and it has recently
emerged that inhibitors of Hsp90b1, together with inhibitors of the other proteins of the Hsp90 family,
are promising classes of anti-cancer drugs in both solid and hematologic malignancies [48].
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On the other hand, from the putative targets of the down-regulated miRNAs in SHH MB CSCs,
we observed the genes involved in both networks and found some crucial genes involved in MB
progression, including Myc, Grb2, Egfr, and Rac1, as shown in Figure 6A,B. In detail, Myc has been
identified as a marker of tumour aggressiveness and SHH activation in the SHH MB subgroup [4,49,50].
Next, we found two components of the Egfr pathway, whose function consists of the adaptor molecule
Grb2 binding to Egfr with the subsequent activation of the pathway. ERK activation has been associated
with MB progression and control of cell-cycle related proteins’ translation, possibly through mTOR
activation [51]. Moreover, SHH induced Rac1 activation and migration of fibroblasts [52], a mechanism
that was also reported in highly invasive MB cells [53].
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MiRNAs have been associated not only with tumorigenesis but also as prognostic biomarkers
with the first study performed by Calin et al. describing the association of loss of miR-15 and
miR-16 expression with a more favourable prognosis in chronic lymphocytic leukemia patients [54].
Unfortunately, even though treatment of MB patients has improved, 30% of patients still die from
the disease [55]. Extending our research, we questioned if any of the putative targets of the SHH MB
CSC miRNAs could have a role in the overall survival of MB patients [2]. Following the description
of Cavalli et al. [2] regarding the four subtypes of SHH MB (α, β, γ, δ) being enriched for different
age groups, we decided to take into consideration the factor of age in overall survival. To this end,
in silico analysis was performed and survival curves were estimated in association with each gene
expression level in MB patients divided in age groups. Firstly, infant (under 3 years of age) and
pediatric (between 4 and 17 years of age) SHH MB patients together, then infant SHH MB, pediatric
SHH MB, and finally adult SHH MB patients. Gene expression was associated with overall survival
(OS) for each category and detailed results are reported in Table 6. Interestingly, expression levels of
several genes were associated with worse overall survival of SHH MB patients. In detail, worse overall
survival in infant and pediatric SHH MB patients was reported with high expression of RHEB and
UBQLN1 and low expression of CHUK, CTNNB1, and DDIT4. MBTPS1, RAF1, TXNDC5, and VCP
high expression and SAR1B and UBE4B low expression were associated with worse overall survival in
infant SHH MB patients. Additionally, high expression of PPP2R1A, RAD23B, RHEB, and UBQLN1
and low expression levels of CHUK and CTNNB1 were observed in pediatric SHH MB patients
with worse overall survival. The absence of common genes among infant SHH MB patients and
the other two categories is noteworthy. Infant MB patient treatment is extremely challenging [56]
and this singularity of infant SHH MB patients could provide useful information since only RAF1
is part of the PI3K-Akt pathway, whereas MBTPS, TXNDC5, VCP, SAR1B, and UBE4B are part of
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the protein processing in endoplasmic reticulum pathway. On the other hand, in pediatric SHH MB
patients, RHEB is involved in the PI3K-Akt pathway, CHUK and CTNNB1 in pathways in cancer and
PPP2R1A, RAD23B, and UBQLN1 are part of the protein processing in endoplasmic reticulum pathway.
Interestingly, two genes belonging in pathways in cancer, EGFR and MAPK3, were identified only
in adult MB patients. Low expression of EGFR and high expression of MAPK3 were associated with
worse OS in adult MB patients. We further investigated the putative targets of SHH MB CSCs taking
into consideration the four SHH subtypes, pediatric SHHα, infant SHHβ, infant SHHγ, and adult
SHHδ, as described by Cavalli et al. [2]. The OS analysis was performed for all putative targets of
SHH MB CSC miRNAs for each SHH subtype and the statistically significant results are reported
in Table 7. In detail, worse OS was associated with CTNNB1, PDIA3, and RAF1 low expression and
RAD23B, RHEB, UBQLN1, and YWHAH high expression in pediatric SHHα patients. Notably, CTNNB1,
RAD23B, RHEB, and UBQLN1 were also reported in pediatric MB patients (Table 6). Infant SHHβ
patients were associated with worse OS when low expression of UBE4B was observed and this gene
was also reported in infant MB patients (Table 6). None of the putative targets of the SHH MB CSC
miRNAs was associated with worse OS in infant SHHγ, a subtype characterised by a good prognosis.
Finally, in adult SHHδ patients low expression of CHUK and DNAJB11 were associated with worse OS,
these genes were not reported in the analysis regarding adult MBs (Table 6).
Whether the genes of interest reported in Table 6 could be characteristic only of SHH MB patients
led to further in silico analysis of the gene expression levels between WNT, SHH, Group 3, and Group
4 MB patients and the results are reported in Table 8. Interestingly, a statistically significant higher
expression of CTNNB1, DDIT4 was observed in infant and pediatric SHH MB patients, whose low
expression was associated with worse OS. Moreover, in the same age group higher expression of
RHEB was observed in Group 4 MB patients compared to other MB subgroups, whose high expression
reported a worse OS. Low expression of MBTPS1 was observed in infant SHH and WNT MB patients
compared to Group 3 and Group 4 MB patients and its high expression was associated with a worse
OS. When comparing only pediatric MB patients the high expression of CTNNB1 was observed in SHH
MB patients compared to the other subgroups and its low expression was linked to worse OS. Of note,
lower expression of RAD23B and UBQLN1 was observed in pediatric SHH MB when compared to
other subgroups and their high expression was associated to worse overall survival. Moreover, in
WNT pediatric patients low expression of RHEB was observed when compared to other subgroups
and its high expression was reported in patients with worse OS. Finally, in adult SHH MB patients
high expression of EGFR was observed when compared to other MB subgroups and its low expression
was related with worse OS.
Recently, researchers have also focused their research in understanding the GLI crosstalk with
other pathways in order to develop possible combinational treatments [57]. Specifically, EGFR and GLI
crosstalk has been reported in MB [58], whereas in other tumour contexts such as anaplastic thyroid
cancer, triple breast cancer, and colon cancer GLI crosstalk has been reported with RAS-BRAF-ERK [59],
WNT [60], and WNT/β-catenin [61] signalling pathways, respectively.
Our results report changes in the enriched pathways and changes in the number of genes that
participate in each pathway, shedding light on another aspect of SHH MBs and identifying novel
molecules and pathways that should be taken into consideration in future studies.
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Table 6. Overall survival of SHH MB patients (GEO ID: gse85217); df, degrees of freedom.
Infant and Pediatric SHH MB Patients (Infant: 0–3 Years n = 50, Pediatric: 4–10 Years n = 45; 10–17 Years n = 26; Total
n = 121), df = 1, chi, chi Squared Test.
Gene Affymetrix Probe BonferroniAdjusted p-Values chi Raw p-Value
Worse Overall
Survival with
CHUK 7935707 2.50 × 10−2 13.54 2.30 × 10−4 Low expression
CTNNB1 8079021 1.90 × 10−5 27.27 1.80 × 10−7 Low expression
DDIT4 7928308 2.00 × 10−2 13.93 1.90 × 10−4 Low expression
RHEB 8143957 2.00 × 10−3 18.31 1.90 × 10−5 High expression
UBQLN1 8161988 1.90 × 10−2 14.05 1.80 × 10−4 High expression
Infant SHH MB Patients (Infant: 0–3 Years n = 50), df = 1
Gene Affymetrix Probe Bonferroni-Adjustedp-Values chi Raw p-Value
Worse Overall
Survival with
MBTPS1 8003089 4.90 × 10−2 10.20 1.40 × 10−3 High expression
RAF1 8085374 4.70 × 10−2 10.27 1.40 × 10−3 High expression
SAR1B 8114193 3.30 × 10−4 19.64 9.40 × 10−6 Low expression
TXNDC5 8123802 1.80 × 10−2 12.10 5.00 × 10−4 High expression
UBE4B 7897527 6.20 × 10−3 14.05 1.80 × 10−4 Low expression
VCP 8160914 4.20 × 10−2 10.47 1.20 × 10−3 High expression
Pediatric SHH MB Patients (Pediatric: 4–10 Years n = 45; 10–17 Years n = 26, Total n = 71), df = 1, chi, chi Squared Test.
Gene Affymetrix Probe Bonferroni-Adjustedp-Values chi Raw p-Value
Worse Overall
Survival with
CHUK 7935707 3.20 × 10−2 11.87 5.70 × 10−4 Low expression
CTNNB1 8079021 1.40 × 10−6 31.02 2.50 × 10−8 Low expression
PPP2R1A 8030881 2.40 × 10−2 12.39 4.30 × 10−4 High expression
RAD23B 8157125 2.40 × 10−4 21.17 4.20 × 10−6 High expression
RHEB 8143957 3.10 × 10−2 11.93 5.50 × 10−4 High expression
UBQLN1 8161988 4.70 × 10−5 24.27 8.40 × 10−7 High expression
Adult SHH MB Patients (Adult: >18 years, n = 49), df = 1, chi, chi Squared Test.
Gene Affymetrix Probe Bonferroni-Adjustedp-Values chi Raw p-Value
Worse Overall
Survival with
EGFR 8132860 4.20 × 10−2 10.45 1.20 × 10−3 Low expression
MAPK3 8000811 3.90 × 10−2 10.59 1.10 × 10−3 High expression
Table 7. Overall survival of SHH MB patients, divided in the four SHH subtypes (GEO ID: gse85217).
SHHα MB Pediatric Patients (n = 41), df = 1, chi, chi Squared Test.
Gene Affymetrix Probe Bonferroni-Adjustedp-Values chi Raw p-Value
Worse Overall
Survival with
CTNNB1 8079021 8.90 × 10−3 12.82 3.40 × 10−4 Low expression
PDIA3 7983274 2.50 × 10−2 10.93 9.40 × 10−4 Low expression
RAD23B 8157125 7.30 × 10−5 21.95 2.80 × 10−6 High expression
RAF1 8085374 1.70 × 10−2 11.60 6.60 × 10−4 Low expression
RHEB 8143957 4.10 × 10−2 9.97 1.60 × 10−3 High expression
UBQLN1 8161988 3.80 × 10−5 23.18 1.50 × 10−6 High expression
YWHAH 8072577 1.50 × 10−2 11.88 5.70 × 10−4 High expression
SHHβ MB Infant Patients (n = 21), df = 1, chi, chi Squared Test.
Gene Affymetrix Probe Bonferroni-Adjustedp-Values chi Raw p-Value
Worse Overall
Survival with
UBE4B 7897527 4.60 × 10−2 7.11 7.70 × 10−3 Low expression
SHHγ MB Infant Patients (n = 25)
Gene Affymetrix Probe Bonferroni-Adjustedp-Values chi Raw p-Value
Worse Overall
Survival with
SHHδ MB Adult Patients (n = 41), df = 1, chi, chi Squared Test.
Gene Affymetrix Probe Bonferroni-Adjustedp-Values chi Raw p-Value
Worse Overall
Survival with
CHUK 7935707 1.20 × 10−2 12.20 4.80 × 10−4 Low expression
DNAJB11 8084634 6.00 × 10−3 13.57 2.30 × 10−4 Low expression
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Table 8. Comparison of expression levels of genes of interest (Table 6) in WNT, SHH, Group 3,
and Group 4 subtypes (GEO ID: gse85217).
Infant and Pediatric MB Patients (SHH n = 146, WNT n = 51, Group 3 n = 131, Group 4 n = 300)
Gene AffymetrixProbe Expression
Group 3 vs. SHH
p-Value
Group 4 vs. SHH
p-Value
WNT vs. SHH
p-Value
Worse Overall
Survival with
CHUK 7935707 Lowest in SHH 5.70 × 10−15 5.00 × 10−13 2.30 × 10−4 Low expression
CTNNB1 8079021 Highest in SHH 1.70 × 10−24 1.60 × 10−36 1.50 × 10−9 Low expression
DDIT4 7928308 Highest in SHH 1.10 × 10−6 3.90 × 10−44 7.80 × 10−6 Low expression
RHEB 8143957 Highest in Group 4 0.87 1.00 × 10−2 9.90 × 10−4 High expression
UBQLN1 8161988 Highest in Group 3and Group 4 3.40 × 10
−6 2.00 × 10−16 0.15 High expression
Infant MB patients (SHH n = 62, WNT n = 1, Group 3 n = 24, Group 4 n = 11)
Gene AffymetrixProbe Expression
Group 3 vs. SHH
p-Value
Group 4 vs. SHH
p-Value
WNT vs. SHH
p-Value
Worse Overall
Survival with
MBTPS1 8003089 Lowest in SHH 9.10 × 10−4 1.60 × 10−4 - High expression
RAF1 8085374 - 0.21 0.34 - High expression
SAR1B 8114193 Lowest in SHH 2.20 × 10−9 1.10 × 10−4 - Low expression
TXNDC5 8123802 - 0.01 0.31 - High expression
UBE4B 7897527 Highest in Group 3and Group 4 0.27 1.80 × 10
−3 - Low expression
VCP 8160914 - 0.32 0.07 - High expression
Pediatric MB patients (SHH n = 84, WNT n = 50, Group 3 n = 107, Group 4 n = 289)
Gene AffymetrixProbe Expression
Group 3 vs. SHH
p-Value
Group 4 vs. SHH
p-Value
WNT vs. SHH
p-Value
Worse Overall
Survival with
CHUK 7935707 Lowest in SHH 5.80 × 10−15 1.20 × 10−14 3.00 × 10−6 Low expression
CTNNB1 8079021 Highest in SHH 3.50 × 10−14 5.90 × 10−20 8.10 × 10−6 Low expression
PPP2R1A 8030881 - 0.09 0.02 0.49 High expression
RAD23B 8157125 Lowest in SHH 4.20 × 10−13 9.10 × 10−17 1.80 × 10−7 High expression
RHEB 8143957 Lowest in WNT 0.87 5.30 × 10−12 2.10 × 10−4 High expression
UBQLN1 8161988 Lowest in SHH 1.40 × 10−8 9.10 × 10−23 5.20 × 10−3 High expression
Adult MB patients (SHH n = 69, WNT n = 13, Group 3 n = 5, Group 4 n = 14)
Gene AffymetrixProbe Expression
Group 3 vs. SHH
p-Value
Group 4 vs. SHH
p-Value
WNT vs. SHH
p-Value
Worse Overall
Survival with
EGFR 8132860 Highest in SHH 1.20 × 10−3 2.60 × 10−4 5.00 × 10−4 Low expression
MAPK3 8000811 Lowest in WNTand Group 3 7.10 × 10
−3 0.6 0.03 High expression
3. Materials and Methods
Unless otherwise specified, all commercial products were used in accordance with the
manufacturer’s protocol.
3.1. SHH MB CSCs and NSCs
Murine SHH MB CSCs were derived, as previously described, from spontaneous tumours arisen
in Ptch1+/− mice [20], maintained as in Reference [23] and RNA extraction was performed as in
Reference [62]. NSC mirnome data were obtained from our recently published manuscript [26].
Animal experiments were performed according to the European Community Council Directive
2010/63/EU and were approved by the local Ethics Committee for Animal Experiments (Prot. N
03/2013, 12/March/2013) of the Sapienza University of Rome.
3.2. miRNA-Sequencing
Three biological replicates of SHH MB CSCs were subjected to miRNA-sequencing, quality control,
mapping, quantification and differential expression analysis was performed between SHH MB
CSCs and NSCs, as previously described [26]. In detail, an average of 10.48 ± 0.748 million
reads per biological replicate were obtained by the sequencing and quality control was performed
using the FastQC tool (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/, accessed on
01/Februay/2017 before mapping where an average of 92% of reads with a quality score >30 were
obtained. All sequenced single-end reads (31 bases) were aligned to the to the Mus musculus
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small RNA library (12-2013), (miRBase V20) using the Genomatix Mining Station (GMS, Sesame
2.4, https://www.genomatix.de/, accessed on 19/February/2017) resulting in an average of 79%
mapping. Differential expression analysis was performed using the miRNA-seq reads of SHH MB
CSCs vs NSCs in the Genomatix Genome Analyzer (GGA, v3.30126, https://www.genomatix.de/,
accessed on 21/February/2017) using the DESeq2 method. Differences characterised by a minimum
log2 fold change of 1 and an adjusted p-value of < 0.05 (Benjamini–Hochberg correction for multiple
testing) were statistically significant.
3.3. mRNA-Sequencing
Three biological replicates of SHH MB CSCs were subjected to mRNA sequencing, quality control,
mapping and transcript abundance were obtained using the TopHat/Cufflinks pipeline, as previously
described [26]. In detail, an average of 80.91 ± 5.41 million reads per biological replicate were
obtained by the sequencing and quality control was performed using the FastQC tool (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/, accessed on 1 February 2017) before mapping where
we obtained an average of 86% of reads with a quality score >30. All sequenced 70mer paired-end
reads were aligned to the Mus musculus genome (GRCm38 mm10 ENSEMBL) using TopHat (version
2.0.11, John Hopkins University, Baltimore, MD, USA) and resulted in an average of 80% mapping.
Transcript assembly was performed with Cufflinks (version 2.2.2, University of Washington, Seattle,
WA, USA) and transcript abundance was estimated using fragments per kilobase of exon per million
fragments mapped (FPKM) values resulting in an average of 14,410 transcripts per biological replicate.
3.4. RNA Extraction and Gene Expression Analysis
Total RNA was isolated from cells using Trireagent (Ambion, Carlsbad, CA, USA) and
reverse transcribed in cDNA as previously described [26]. cDNA was analysed in quantitative
RT-PCR (qRT-PCR) using ViiA™ 7 Real-Time PCR System (Applied Biosystems, Waltham, MA,
USA) and SensiFAST™ Probe Lo-ROX (Bioline Reagents Limited, London, UK). For each
sample 10 ng of cDNA were used in qPCR. We selected TaqMan gene expression assays from
Applied Biosystems (Applied Biosystems, Waltham, MA, USA): Ccnd1 (Mm00432359_m1); Hdac2
(Mm00515108_m1); Cdkn1a (Mm04205640_g1); Atf4 (Mm00515325_g1); Bcat1 (Mm00500289_m1);
Ccnd2 (Mm00438070_m1); Egfr (Mm01187858_m1); Myc (Mm00487804_m1); Hif1a (Mm00468869_m1).
β-2-Microglobulin (Mm00437762_m1), Hprt (Mm03024075_m1), and Actb (Mm02619580_g1) were
used as endogenous controls.
MiRNA expression was assessed with TaqMan probes (Applied Biosystems, Waltham, MA, USA),
as previously described [27], using the following miRNAs: miR-20a (Code: 000580); miR-222-5p (Code:
463390_mat); miR-34a (Code: 000426); miR-345-5p (Code: 002528); miR-210-5p (Code: 462444_mat);
miR-193a-5p (Code: 002577); miR-200a-3p (Code: 000502). U6 snRNA (Code: 001973) was used as
endogenous control.
mRNA quantification was expressed in arbitrary units and each amplification reaction was
performed in triplicate. All data were evaluated using the 2-∆∆CT method and values were normalised
to three endogenous controls.
3.5. Pathway Enrichment Analysis
DAVID (https://david.ncifcrf.gov/, accessed on 27 February 2017) [63] was used to perform
pathway enrichment analysis using the KEGG (Kyoto Encyclopedia of Genes and Genomes) database
for all the transcripts reported from the mRNA-sequencing and pathways enriched for more than 45
genes that were deemed of interest. Up-regulated miRNAs in SHH MB CSCs were used as input to
obtain the enriched pathways and the same analysis was performed for the down-regulated miRNAs
in SHH MB CSCs. Pathways with FDR < 0.05 and p < 0.05 were statistically significant and are reported
in detail in Tables 3–5 and Tables S4–S6, respectively.
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3.6. miRNA Putative Targets
Identification of miRNA putative targets was performed with miRSystem (http://mirsystem.
cgm.ntu.edu.tw/, accessed on 12 January 2018)) [64] and target predictions for up-regulated and
down-regulated miRNAs in SHH MB CSCs were obtained. The predicted targets were intersected with
the genes included in the enriched pathways for the up-regulated (Tables S7–S9) and down-regulated
miRNAs (Tables S10 and S11).
3.7. Functional Networks
The construction of the functional networks was performed with String DB (https://string-
db.org/, accessed on 30 January 2018)) [65]. The genes of interest reported in Tables S7–S9 for the
up-regulated miRNAs and in Tables S10 and S11 for the down-regulated miRNAs in SHH MB CSCs
were used as input after the exclusion of the common genes between the predicted targets of the
up-regulated and down-regulated miRNAs of the same pathway. Medium confidence interaction
score was selected and networks were exported from the database.
3.8. In Silico Analysis of SHH MB Patients’ Overall Survival
Gene expression levels of infant (0–3 years n = 50), pediatric (4–10 years n = 45; 10–17 years
n = 26, total n = 71), adult (>18 years n = 49) SHH MB patients, and SHHα (n = 41), SHHβ (n = 21),
SHHγ (n = 25), and SHHδ (n = 41) MB patients (GEO ID: gse85217) were queried in R2 platform
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi, accessed on 12 March 2018 and 29 July 2018) [66],
using the probes reported in Tables 6 and 7, and Kaplan–Meier survival curves were plotted along
with the statistical analysis and Bonferroni-adjusted p-values < 0.05 (Tables 6 and 7) were considered as
statistically significant. Gene expression levels of infant and pediatric MB patients (SHH n = 146, WNT
n = 51, Group 3 n = 131, Group 4 n = 300), infant MB patients (SHH n = 62, WNT n = 1, Group 3 n = 24,
Group 4 n = 11), pediatric MB patients (SHH n = 84, WNT n = 50, Group 3 n = 107, Group 4 n = 289),
and adult MB patients (SHH n = 69, WNT n = 13, Group 3 n = 5, Group 4 n = 14) (GEO ID: gse85217)
were queried in R2 platform and compared for each age group among the four MB subgroups (WNT,
SHH, Group 3, and Group 4) using the probes reported in Table 8.
4. Conclusions
This study allowed us to focus on the CSC compartment of SHH MB and the data obtained from
mirnome and transcriptome sequencing brought in evidence of the implicated pathways in SHH MB
CSCs. The activation of PI3K-Akt pathway has been reported in MBs and new studies are focusing
on the combinational treatment of MB with SMO and PI3K-Akt inhibitors. On this basis, this study
presents other candidate pathways and genes whose inhibition or activation could be the foundation
of future functional studies, leading to a shift in the landscape of survival in SHH MB patients.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/8/
2326/s1.
Author Contributions: E.F., E.M. and Z.M.B. conceived and designed research; A.P., L.A., C.S., F.G. (Francesca
Gianno), G.C., M.C., E.M., Z.M.B. performed research; E.F., E.D.S., A.P. contributed reagents/analytic tools; A.P.,
L.A., E.M., Z.M.B. acquired and analysed data; Z.M.B., F.G. (Felice Giangaspero) and E.F. drafted the manuscript;
all co-authors contributed to the final version of the manuscript.
Acknowledgments: The work was partially supported by Sapienza University Research Grants 2016 and 2017,
Agenzia Spaziale Italiana (ASI), Istituto Italiano di Tecnologia (IIT) and Ricerca Corrente 2017 to E. Miele.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2018, 19, 2326 16 of 19
References
1. Northcott, P.A.; Buchhalter, I.; Morrissy, A.S.; Hovestadt, V.; Weischenfeldt, J.; Ehrenberger, T.; Gröbner, S.;
Segura-Wang, M.; Zichner, T.; Rudneva, V.A. The whole-genome landscape of medulloblastoma subtypes.
Nature 2017, 547, 311–317. [CrossRef] [PubMed]
2. Cavalli, F.M.; Remke, M.; Rampasek, L.; Peacock, J.; Shih, D.J.; Luu, B.; Garzia, L.; Torchia, J.;
Nor, C.; Morrissy, A.S. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 2017,
31, 737–754.e6. [CrossRef] [PubMed]
3. Morrissy, A.S.; Cavalli, F.M.; Remke, M.; Ramaswamy, V.; Shih, D.J.; Holgado, B.L.; Farooq, H.; Donovan, L.K.;
Garzia, L.; Agnihotri, S. Spatial heterogeneity in medulloblastoma. Nat. Genet. 2017, 49, 780. [CrossRef]
[PubMed]
4. Northcott, P.; Shih, D.J.; Peacock, J.; Garzia, L.; Morrissy, A.; Zichner, T.; Stütz, A.; Korshunov, A.; Reimand, J.;
Schumacher, S.; Beroukhim, R. Subgroup-specific structural variation across 1000 medulloblastoma genomes.
Nature 2012, 488, 49–56. [CrossRef] [PubMed]
5. Ferretti, E.; Di Marcotullio, L.; Gessi, M.; Mattei, T.; Greco, A.; Po, A.; De Smaele, E.; Giangaspero, F.;
Riccardi, R.; Di Rocco, C.; et al. Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by
hedgehog signaling identify distinct medulloblastoma subsets. Oncogene 2006, 25, 7267–7273. [CrossRef]
[PubMed]
6. Louis, D.N.; Perry, A.; Reifenberger, G.; Von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.;
Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization classification of tumors of the
central nervous system: A summary. Acta Neuropathol. 2016, 131, 803–820. [CrossRef] [PubMed]
7. Rimkus, T.K.; Carpenter, R.L.; Qasem, S.; Chan, M.; Lo, H.-W. Targeting the sonic hedgehog signaling
pathway: Review of smoothened and GLI inhibitors. Cancers 2016, 8, 22. [CrossRef] [PubMed]
8. De Smaele, E.; Ferretti, E.; Gulino, A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for
the treatment of advanced cancers. Curr. Opin. Investig. Drugs 2010, 11, 707–718. [PubMed]
9. Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.;
Hann, C.L.; Brahmer, J.R. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl.
J. Med. 2009, 361, 1164–1172. [CrossRef] [PubMed]
10. Basset-Seguin, N.; Sharpe, H.J.; de Sauvage, F.J. Efficacy of Hedgehog pathway inhibitors in basal cell
carcinoma. Mol. Cancer Ther. 2015, 14, 633–641. [CrossRef] [PubMed]
11. Bendell, J.; Andre, V.; Ho, A.; Kudchadkar, R.; Migden, M.; Infante, J.; Tiu, R.V.; Pitou, C.; Tucker, T.; Brail, L.
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve
and Previously Treated Basal Cell Carcinoma. Clin. Cancer Res. 2018, 24, 2082–2091. [CrossRef] [PubMed]
12. Yauch, R.; Dijkgraaf, G.; Alicke, B.; Januario, T.; Ahn, C.; Holcomb, T.; Pujara, K.; Stinson, J.; Callahan, C.;
Tang, T.; et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Science 2009, 326, 572–574. [CrossRef] [PubMed]
13. Ransohoff, K.; Sarin, K.; Tang, J. Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma.
J. Clin. Oncol. 2015, 33, 2692–2694. [CrossRef] [PubMed]
14. Brechbiel, J.; Miller-Moslin, K.; Adjei, A.A. Crosstalk between hedgehog and other signaling pathways as a
basis for combination therapies in cancer. Cancer Treat. Rev. 2014, 40, 750–759. [CrossRef] [PubMed]
15. Li, Q.-R.; Zhao, H.; Zhang, X.-S.; Lang, H.; Yu, K. Novel-smoothened inhibitors for therapeutic targeting
of naïve and drug-resistant hedgehog pathway-driven cancers. Acta Pharmacol. Sin. 2018, 1. [CrossRef]
[PubMed]
16. Bjerkvig, R.; Tysnes, B.B.; Aboody, K.S.; Najbauer, J.; Terzis, A. The origin of the cancer stem cell: Current
controversies and new insights. Nat. Rev. Cancer 2005, 5, 899. [CrossRef] [PubMed]
17. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.;
Dirks, P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396–401. [CrossRef]
[PubMed]
18. Wu, X.; Northcott, P.A.; Croul, S.; Taylor, M.D. Mouse models of medulloblastoma. Chin. J. Cancer 2011,
30, 442. [CrossRef] [PubMed]
19. Goodrich, L.V.; Milenkovic´, L.; Higgins, K.M.; Scott, M.P. Altered neural cell fates and medulloblastoma in
mouse patched mutants. Science 1997, 277, 1109–1113. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2326 17 of 19
20. Po, A.; Ferretti, E.; Miele, E.; De Smaele, E.; Paganelli, A.; Canettieri, G.; Coni, S.; Di Marcotullio, L.;
Biffoni, M.; Massimi, L.; et al. Hedgehog controls neural stem cells through p53-independent regulation of
Nanog. EMBO J. 2010, 29, 2646–58. [CrossRef] [PubMed]
21. Ronci, M.; Catanzaro, G.; Pieroni, L.; Po, A.; Besharat, Z.M.; Greco, V.; Levi Mortera, S.; Screpanti, I.;
Ferretti, E.; Urbani, A. Proteomic analysis of human sonic hedgehog (SHH) medulloblastoma stem-like cells.
Mol. Biosyst. 2015, 11, 1603–1611. [CrossRef] [PubMed]
22. Catanzaro, G.; Besharat, Z.M.; Garg, N.; Ronci, M.; Pieroni, L.; Miele, E.; Mastronuzzi, A.; Carai, A.; Alfano, V.;
Po, A.; et al. microRNAs-proteomic networks characterizing human medulloblastoma-SLCs. Stem Cells Int.
2016, 2016. [CrossRef] [PubMed]
23. Miele, E.; Valente, S.; Alfano, V.; Silvano, M.; Mellini, P.; Borovika, D.; Marrocco, B.; Po, A.; Besharat, Z.M.;
Catanzaro, G. The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer
stem cells. Oncotarget 2017, 8, 68557. [CrossRef] [PubMed]
24. Gulino, A.; Ferretti, E.; De Smaele, E. Hedgehog signalling in colon cancer and stem cells. EMBO Mol. Med.
2009, 1, 300–302. [CrossRef] [PubMed]
25. Po, A.; Silvano, M.; Miele, E.; Capalbo, C.; Eramo, A.; Salvat, i. V.; Todaro, M.; Besharat, Z.M.; Catanzaro, G.;
Cucchi, D.; et al. Noncanonical GLI1 signalling promotes stemness features and in vivo growth in lung
adenocarcinoma. Oncogene 2017, 36, 4641–4652. [CrossRef] [PubMed]
26. Besharat, Z.M.; Abballe, L.; Cicconardi, F.; Bhutkar, A.; Grassi, L.; Le Pera, L.; Moretti, M.; Chinappi, M.;
D’Andrea, D.; Mastronuzzi, A.; et al. Foxm1 controls a pro-stemness microRNA network in neural stem
cells. Sci. Rep. 2018, 8, 3523. [CrossRef] [PubMed]
27. Ferretti, E.; De Smaele, E.; Miele, E.; Laneve, P.; Po, A.; Pelloni, M.; Paganelli, A.; Di Marcotullio, L.;
Caffarelli, E.; Screpanti, I.; et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal
progenitor and tumour cells. EMBO J. 2008, 27, 2616–2627. [CrossRef] [PubMed]
28. Ferretti, E.; De Smaele, E.; Po, A.; Di Marcotullio, L.; Tosi, E.; Espinola, M.S.B.; Di Rocco, C.; Riccardi, R.;
Giangaspero, F.; Farcomeni, A.; et al. MicroRNA profiling in human medulloblastoma. Int. J. Cancer 2009,
124, 568–577. [CrossRef] [PubMed]
29. Uziel, T.; Karginov, F.V.; Xie, S.; Parker, J.S.; Wang, Y.-D.; Gajjar, A.; He, L.; Ellison, D.; Gilbertson, R.J.;
Hannon, G. The miR-17∼92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma.
Proc. Natl. Acad. Sci. USA 2009, 106, 2812–2817. [CrossRef] [PubMed]
30. Northcott, P.A.; Fernandez-L, A.; Hagan, J.P.; Ellison, D.W.; Grajkowska, W.; Gillespie, Y.; Grundy, R.;
Van Meter, T.; Rutka, J.T.; Croce, C.M.; et al. The miR-17/92 polycistron is up-regulated in Sonic
Hedgehog–driven medulloblastomas and induced by N-myc in Sonic Hedgehog–treated cerebellar neural
precursors. Cancer Res. 2009, 69, 3249–3255. [CrossRef] [PubMed]
31. Murphy, B.L.; Obad, S.; Bihannic, L.; Ayrault, O.; Zindy, F.; Kauppinen, S.; Roussel, M.F. Silencing of the
miR-17∼ 92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013, 73, 7068–7078. [CrossRef]
[PubMed]
32. Tech, K.; Gershon, T.R. Energy metabolism in neurodevelopment and medulloblastoma. Transl. Pediatr. 2015,
4, 12. [PubMed]
33. Clarke, H.J.; Chambers, J.E.; Liniker, E.; Marciniak, S.J. Endoplasmic reticulum stress in malignancy.
Cancer Cell 2014, 25, 563–573. [CrossRef] [PubMed]
34. Hartmann, W.; Digon-Söntgerath, B.; Koch, A.; Waha, A.; Endl, E.; Dani, I.; Denkhaus, D.; Goodyer, C.G.;
Sörensen, N.; Wiestler, O.D. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma
cell proliferation and is associated with reduced expression of PTEN. Clin. Cancer Res. 2006, 12, 3019–3027.
[CrossRef] [PubMed]
35. Hambardzumyan, D.; Becher, O.J.; Rosenblum, M.K.; Pandolfi, P.P.; Manova-Todorova, K.; Holland, E.C.
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation
in medulloblastoma in vivo. Genes Dev. 2008, 22, 436–448. [CrossRef] [PubMed]
36. Mohan, A.L.; Friedman, M.D.; Ormond, D.R.; Tobias, M.; Murali, R.; Jhanwar-Uniyal, M. PI3K/mTOR
signaling pathways in medulloblastoma. Anticancer Res. 2012, 32, 3141–3146. [PubMed]
37. Crespo, S.; Kind, M.; Arcaro, A. The role of the PI3K/AKT/mTOR pathway in brain tumor metastasis.
J. Cancer Metastasis Treat. 2016, 2, 81. [CrossRef]
Int. J. Mol. Sci. 2018, 19, 2326 18 of 19
38. Frasson, C.; Rampazzo, E.; Accordi, B.; Beggio, G.; Pistollato, F.; Basso, G.; Persano, L. Inhibition of PI3K
signalling selectively affects medulloblastoma cancer stem cells. BioMed Res. Int. 2015, 2015, 973912.
[CrossRef] [PubMed]
39. Buonamici, S.; Williams, J.; Morrissey, M.; Wang, A.; Guo, R.; Vattay, A.; Hsiao, K.; Yuan, J.; Green, J.;
Ospina, B. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in
medulloblastoma. Sci. Transl. Med. 2010, 2, 51ra70. [CrossRef] [PubMed]
40. Thomson, D.W.; Dinger, M.E. Endogenous microRNA sponges: Evidence and controversy. Nat. Rev. Genet.
2016, 17, 272. [CrossRef] [PubMed]
41. Pasquinelli, A.E. MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal
relationship. Nat. Rev. Genet. 2012, 13, 271. [CrossRef] [PubMed]
42. MacDonald, T.J.; Brown, K.M.; LaFleur, B.; Peterson, K.; Lawlor, C.; Chen, Y.; Packer, R.J.; Cogen, P.;
Stephan, D.A. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as
therapeutic targets for metastatic disease. Nat. Genet. 2001, 29, 143. [CrossRef] [PubMed]
43. Zhao, X.; Ponomaryov, T.; Ornell, K.J.; Zhou, P.; Dabral, S.K.; Pak, E.; Li, W.; Atwood, S.X.; Whitson, R.J.;
Chang, A.L.S. RAS/MAPK activation drives resistance to Smo inhibition, metastasis, and tumor evolution
in Shh pathway–dependent tumors. Cancer Res. 2015, 75, 3623–3635. [CrossRef] [PubMed]
44. Emmenegger, B.A.; Hwang, E.I.; Moore, C.; Markant, S.L.; Brun, S.N.; Dutton, J.W.; Read, T.-A.; Fogarty, M.P.;
Singh, A.R.; Durden, D.L. Distinct roles for fibroblast growth factor signaling in cerebellar development and
medulloblastoma. Oncogene 2013, 32, 4181. [CrossRef] [PubMed]
45. Guessous, F.; Yang, Y.; Johnson, E.; Marcinkiewicz, L.; Smith, M.; Zhang, Y.; Kofman, A.; Schiff, D.;
Christensen, J.; Abounader, R. Cooperation between c-Met and focal adhesion kinase family members
in medulloblastoma and implications for therapy. Mol. Cancer Ther. 2012, 11, 288–297. [CrossRef] [PubMed]
46. Tripolitsioti, D.; Kumar, K.S.; Neve, A.; Migliavacca, J.; Capdeville, C.; Rushing, E.J.; Ma, M.; Kijima, N.;
Sharma, A.; Pruschy, M. MAP4K4 controlled integrin β1 activation and c-Met endocytosis are associated
with invasive behavior of medulloblastoma cells. Oncotarget 2018, 9, 23220. [CrossRef] [PubMed]
47. Hong, F.; Liu, B.; Chiosis, G.; Gewirth, D.T.; Li, Z. Alpha 7 helix region of αlpha I domain is crucial for
integrin binding to ER chaperone gp96: A potential therapeutic target for cancer metastasis. J. Biol. Chem.
2013. [CrossRef] [PubMed]
48. Usmani, S.Z.; Bona, R.D.; Chiosis, G.; Li, Z. The anti-myeloma activity of a novel purine scaffold HSP90
inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J. Hematol. Oncol. 2010, 3, 40. [CrossRef]
[PubMed]
49. Kool, M.; Korshunov, A.; Remke, M.; Jones, D.; Schlanstein, M.; Northcott, P.; Cho, Y.; Koster, J.; Schouten-van
Meeteren, A.; van Vuurden, D.; et al. Molecular subgroups of medulloblastoma: An international
meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4
medulloblastomas. Acta Neuropathol. 2012, 123, 473–484. [CrossRef] [PubMed]
50. Northcott, P.; Jones, D.; Kool, M.; Robinson, G.; Gilbertson, R.; Cho, Y.; Pomeroy, S.; Korshunov, A.; Lichter, P.;
Taylor, M.; et al. Medulloblastomics: The end of the beginning. Nat. Rev. Cancer 2012, 12, 818–834. [CrossRef]
[PubMed]
51. Włodarski, P.; Grajkowska, W.; Łojek, M.; Rainko, K.; Józ´wiak, J. Activation of Akt and Erk pathways in
medulloblastoma. Folia Neuropathol. 2006, 44, 214–220. [PubMed]
52. Polizio, A.H.; Chinchilla, P.; Chen, X.; Kim, S.; Manning, D.R.; Riobo, N.A. Heterotrimeric Gi proteins link
Hedgehog signaling to activation of Rho small GTPases to promote fibroblast migration. J. Biol. Chem. 2011,
286, 19589–19596. [CrossRef] [PubMed]
53. Ridgway, L.D.; Wetzel, M.D.; Marchetti, D. Heparanase modulates Shh and Wnt3a signaling in human
medulloblastoma cells. Exp. Ther. Med. 2011, 2, 229–237. [CrossRef] [PubMed]
54. Calin, G.A.; Ferracin, M.; Cimmino, A.; Di Leva, G.; Shimizu, M.; Wojcik, S.E.; Iorio, M.V.; Visone, R.;
Sever, N.I.; Fabbri, M. A MicroRNA signature associated with prognosis and progression in chronic
lymphocytic leukemia. N. Engl. J. Med. 2005, 353, 1793–1801. [CrossRef] [PubMed]
55. Gajjar, A.; Bowers, D.; Karajannis, M.; Leary, S.; Witt, H.; Gottardo, N. Pediatric brain tumors: Innovative
genomic information is transforming the diagnostic and clinical landscape. J. Clin. Oncol. 2015, 33, 2986.
[CrossRef] [PubMed]
56. Lassaletta, A. Medulloblastoma in infants: The never-ending challenge. Lancet Oncol. 2018, 19, 720–721.
[CrossRef]
Int. J. Mol. Sci. 2018, 19, 2326 19 of 19
57. Pandolfi, S.; Stecca, B. Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic
pathways: Implications for cancer therapy. Expert Rev. Mol. Med. 2015, 17. [CrossRef] [PubMed]
58. Götschel, F.; Berg, D.; Gruber, W.; Bender, C.; Eberl, M.; Friedel, M.; Sonntag, J.; Rüngeler, E.; Hache, H.;
Wierling, C. Synergism between Hedgehog-GLI and EGFR signaling in Hedgehog-responsive human
medulloblastoma cells induces downregulation of canonical Hedgehog-target genes and stabilized
expression of GLI1. PLoS ONE 2013, 8, e65403. [CrossRef] [PubMed]
59. Parascandolo, A.; Laukkanen, M.O.; De Rosa, N.; Ugolini, C.; Cantisani, M.C.; Cirafici, A.M.; Basolo, F.;
Santoro, M.; Castellone, M.D. A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic
thyroid cancer: Crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma. Oncotarget
2018, 9, 4496. [CrossRef] [PubMed]
60. Arnold, K.M.; Pohlig, R.T.; Sims-Mourtada, J. Co-activation of Hedgehog and Wnt signaling pathways is
associated with poor outcomes in triple negative breast cancer. Oncol. Lett. 2017, 14, 5285–5292. [CrossRef]
[PubMed]
61. Song, L.; Li, Z.-Y.; Liu, W.-P.; Zhao, M.-R. Crosstalk between Wnt/β-catenin and Hedgehog/Gli signaling
pathways in colon cancer and implications for therapy. Cancer Biol. Ther. 2015, 16, 1–7. [CrossRef] [PubMed]
62. Ferretti, E.; Tosi, E.; Po, A.; Scipioni, A.; Morisi, R.; Espinola, M.; Russo, D.; Durante, C.; Schlumberger, M.;
Screpanti, I.; et al. Notch signaling is involved in expression of thyrocyte differentiation markers and is
down-regulated in thyroid tumors. J. Clin. Endocrinol. Metab. 2008, 93, 4080–4087. [CrossRef] [PubMed]
63. Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using
DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44–57. [CrossRef] [PubMed]
64. Lu, T.-P.; Lee, C.-Y.; Tsai, M.-H.; Chiu, Y.-C.; Hsiao, C.K.; Lai, L.-C.; Chuang, E.Y. miRSystem: An integrated
system for characterizing enriched functions and pathways of microRNA targets. PLoS ONE 2012, 7, e42390.
[CrossRef] [PubMed]
65. Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.;
Santos, A.; Tsafou, K.P. STRING v10: Protein–protein interaction networks, integrated over the tree of life.
Nucl. Acids Res. 2014, 43, D447–D452. [CrossRef] [PubMed]
66. R2 R2: Genomics Analysis and Visualization Platform. Available online: http://r2.amc.nl.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
